VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
You may also be interested in...
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.
Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.